GeneDx Holdings Corp Reports Q1 2026 Earnings Call Summary
GeneDx Holdings (NASDAQ: GDX) reported a $12 million revenue shortfall in Q1 2026 due to lower blended average reimbursement rates and underperformance in non-core business lines. The company is shifting focus toward core genomic products, optimizing unit economics, and adjusting its international strategy for the Fabric Genomics acquisition.
Topics: execution_gap genomics revenue_shortfall whole_genome_sequencing